Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

Listen to Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, as they answer audience questions from a live webinar about how to best use the plethora of active agents and regimens now available for patients with advanced multiple myeloma.
Paul G. Richardson, MD
Program Director
person default
Nina Shah, MD
Peter M. Voorhees, MD
Released: August 24, 2021

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:

  • Treatment after first relapsed
  • Optimal use of CAR T-cell therapy
  • When to use selinexor and belantamab mafodotin
  • COVID-19 vaccinations for patients with myeloma

Information on this Educational Activity

Program Director

Paul G. Richardson, MD

R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research

Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb/Celgene, Karyopharm, Oncopeptides, and Takeda and consulting fees from AstraZeneca, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, and Takeda.

Faculty

Nina Shah, MD

Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California, San Francisco
San Francisco, California

Nina Shah, MD, has disclosed that she has received funds for research from Bluebird Bio, Celgene/Bristol-Myers Squibb, Janssen, Nektar, Poseida, Precision Biosciences, Sutro Biopharma, and TeneoBio and consulting fees for an advisory role from Amgen, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, and Sanofi.
Peter M. Voorhees, MD

Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute
Charlotte, North Carolina

Peter M. Voorhees, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Novartis, Oncopeptides, and SecuraBio and has served on the advisory board for AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Pfizer, and Sanofi.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm
Oncopeptides
Sanofi Genzyme

Related Content

Download these expert-selected slides from Clinical Care Options (CCO) on acute myeloid leukemia to help provide optimal treatment for your patients with AML.

Amir T. Fathi, MD Eunice S. Wang, MD Released: October 21, 2021

Prof. Paul Coppo shares his thoughts on the current management of aTTP using clinical guidelines, biomarkers, and targeted therapies, from Clinical Care Options (CCO)

person default Paul Coppo, MD, PhD Released: October 21, 2021

Shaji Kumar, MD, and Beth Faiman, PhD, share expert guidance on diagnosing and managing patients with AL and ATTR amyloidosis, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: October 21, 2021 Expired: October 20, 2022

Downloadable slideset on diagnosing and managing AL and ATTR amyloidosis, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Released: October 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue